updated 12/14/2010 8:16:15 AM ET 2010-12-14T13:16:15

CHARLOTTE, N.C., Dec. 14, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) will webcast its session at the 2010 Deutsche Bank BioFEST at 11:30 a.m. ET on Tuesday, December 14, 2010.

Dr. Simon Pedder, Chelsea's president and chief executive officer, will provide a brief overview of the company's product pipeline, clinical development status and upcoming milestones prior to answering questions from the audience. The session may be accessed through the Company's web site, www.chelseatherapeutics.com. An archived version of the presentation will be available after the live webcast through January 13, 2011.

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates Droxidopa and CH-1504, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for our products if any are approved for marketing and reliance on key personnel including specifically Dr. Pedder.

CONTACT:  Chelsea Therapeutics
          Investors:
          Kathryn McNeil
          718-788-2856
          mcneil@chelseatherapeutics.com

          Hill & Knowlton
          Media:
          Sean Leous
          212-885-0549
          sean.leous@hillandknowlton.com

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.71%
$30K home equity loan FICO 5.26%
$75K home equity loan FICO 4.70%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.42%
Cash Back Cards 17.94%
17.94%
Rewards Cards 17.14%
17.14%
Source: Bankrate.com